JP2019523008A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523008A5
JP2019523008A5 JP2019504923A JP2019504923A JP2019523008A5 JP 2019523008 A5 JP2019523008 A5 JP 2019523008A5 JP 2019504923 A JP2019504923 A JP 2019504923A JP 2019504923 A JP2019504923 A JP 2019504923A JP 2019523008 A5 JP2019523008 A5 JP 2019523008A5
Authority
JP
Japan
Prior art keywords
recombinant virus
recombinant
virus
administering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019504923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523008A (ja
JP7638061B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044683 external-priority patent/WO2018023114A1/en
Publication of JP2019523008A publication Critical patent/JP2019523008A/ja
Publication of JP2019523008A5 publication Critical patent/JP2019523008A5/ja
Priority to JP2022129037A priority Critical patent/JP2022163182A/ja
Priority to JP2024096293A priority patent/JP2024123088A/ja
Application granted granted Critical
Publication of JP7638061B2 publication Critical patent/JP7638061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019504923A 2016-07-29 2017-07-31 腫瘍溶解性ウイルスによるPTEN-Longの発現 Active JP7638061B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022129037A JP2022163182A (ja) 2016-07-29 2022-08-12 腫瘍溶解性ウイルスによるPTEN-Longの発現
JP2024096293A JP2024123088A (ja) 2016-07-29 2024-06-13 腫瘍溶解性ウイルスによるPTEN-Longの発現

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368822P 2016-07-29 2016-07-29
US62/368,822 2016-07-29
US201762479671P 2017-03-31 2017-03-31
US62/479,671 2017-03-31
PCT/US2017/044683 WO2018023114A1 (en) 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022129037A Division JP2022163182A (ja) 2016-07-29 2022-08-12 腫瘍溶解性ウイルスによるPTEN-Longの発現

Publications (3)

Publication Number Publication Date
JP2019523008A JP2019523008A (ja) 2019-08-22
JP2019523008A5 true JP2019523008A5 (enExample) 2020-09-10
JP7638061B2 JP7638061B2 (ja) 2025-03-03

Family

ID=61016870

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504923A Active JP7638061B2 (ja) 2016-07-29 2017-07-31 腫瘍溶解性ウイルスによるPTEN-Longの発現
JP2022129037A Pending JP2022163182A (ja) 2016-07-29 2022-08-12 腫瘍溶解性ウイルスによるPTEN-Longの発現
JP2024096293A Pending JP2024123088A (ja) 2016-07-29 2024-06-13 腫瘍溶解性ウイルスによるPTEN-Longの発現

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022129037A Pending JP2022163182A (ja) 2016-07-29 2022-08-12 腫瘍溶解性ウイルスによるPTEN-Longの発現
JP2024096293A Pending JP2024123088A (ja) 2016-07-29 2024-06-13 腫瘍溶解性ウイルスによるPTEN-Longの発現

Country Status (8)

Country Link
US (2) US20200085890A1 (enExample)
EP (2) EP3490574B8 (enExample)
JP (3) JP7638061B2 (enExample)
KR (1) KR102780496B1 (enExample)
CN (1) CN110087662A (enExample)
AU (1) AU2017301901B2 (enExample)
SG (1) SG11201900815UA (enExample)
WO (1) WO2018023114A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
EP3833765B1 (en) * 2017-08-09 2026-01-14 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
CN108484780A (zh) * 2018-04-16 2018-09-04 河南大学 一种融合蛋白PTEN-L-p53及其应用
WO2020208609A1 (en) 2019-04-12 2020-10-15 Therapten Biosciences Inc. Compositions and methods to manufacture phosphatase and tensin homolog (pten) fusions
CN114423860A (zh) * 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
CN111763260B (zh) * 2020-06-11 2022-03-29 四川大学华西医院 一种PTEN-Long多克隆抗体及其制备方法和用途
WO2024163335A2 (en) * 2023-01-30 2024-08-08 The Board Of Regents Of The University Of Texas System Pten gene therapy vectors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20080292592A1 (en) * 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
EP1871887A2 (en) * 2005-03-09 2008-01-02 Board of Regents, The University of Texas System NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
BRPI1005951A2 (pt) * 2009-02-17 2016-10-11 Univ Columbia polipeptídeo de fosfatase humana isolada e homológo de tensina longo (pten-longo), composição farmacêutica, método para tratamento de um tumor sólido em um indivíduo, método para inibir crescimento de um tumor sólido em um indivíduo, método para inibir angiogênese em um tumor sólido em um indivíduo, método para induzir apoptose de uma célula vascular epitélial de um vaso sanguíneo em um tumor sólido em um indivíduo, método para tratar um tumor sólido em um indivíduo, polipeptídeo de fósfatase humana e homólogo de tensina longo (pten-longo), pten-longo ou um fragmento desteou o análogo deste, composição, ácido nuclêico isolado que codifica um polipeptídeode fosfatase humana e homólogo de tensina longo (pten-longo), vetor de expressão, célula transformada capaz de expressar polipeptídeo de fosfatase humana e homológo de tensina longo (pten-longo), célula hospedeira capaz de expressar polipeptídeo de fosfatase humana e humológo de tensina longo (pten-longo), processo, molécula de ácido nuclêico isolada, anticorpo isolado, fragmento de anticorpo e fragmento de peptídeo da seq id no: 1 ou seq id no: 5
AU2011218037B2 (en) * 2010-02-17 2016-10-13 The Trustees Of Columbia University In The City Of New York Use of PTEN-long leader sequence for transmembrane delivery of molecules
KR101497035B1 (ko) * 2010-04-26 2015-02-27 주식회사 녹십자 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터
EP2494978A1 (en) * 2011-03-03 2012-09-05 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
WO2013169388A1 (en) * 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy
CA2904802C (en) * 2013-03-13 2021-03-30 Zhong Li Microvesicle and method for producing the same
KR102490462B1 (ko) * 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
GB201408297D0 (en) * 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer

Similar Documents

Publication Publication Date Title
Sivanandam et al. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds
Peter et al. Oncolytic adenovirus in cancer immunotherapy
Webb et al. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response
JP2022163182A5 (enExample)
Sánchez et al. African swine fever virus controls the host transcription and cellular machinery of protein synthesis
Bridle et al. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines
WO2018073393A3 (en) Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
Wang et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy
NZ749586A (en) Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
JP2018500006A5 (enExample)
MD4748B1 (ro) Terapii imunooncolitice
WO2011119925A3 (en) Synthetic herpes simplex viruses for treatment of cancers
Toribio et al. Inhibition of host translation by virus infection in vivo
Tian et al. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy
JP2014523236A (ja) 腫瘍溶解性強化B型ヒトアデノウイルスAd11突然変異体の構築とその応用
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
MX2021007860A (es) Poxvirux deficiente en m2.
JP2018517419A5 (enExample)
Xu et al. Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma
CN103740756B (zh) 一种可调控删除的非病毒游离载体及其构建方法
RU2019125436A (ru) Новый подход к иммунотерапии, нацеленной на vegfr-2
Kowalczyk et al. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack
Brachtlova et al. Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens
RU2018115534A (ru) Противоопухолевая композиция